Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Target Price of $10.00

Shares of Emergent Biosolutions Inc. (NYSE:EBS) have been given an average rating of “Hold” by the six research firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.00.

A number of analysts have recently issued reports on the stock. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research note on Friday, August 21st. They issued an “underweight” rating on the stock. Weiss Ratings raised shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, August 21st. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research report on Wednesday, September 9th.

Emergent Biosolutions Price Performance

NYSE:EBS opened at $5.88 on Friday. The company has a current ratio of 4.58, a quick ratio of 2.95 and a debt-to-equity ratio of 1.62. Emergent Biosolutions has a 52-week low of $4.36 and a 52-week high of $14.06. The stock has a 50-day simple moving average of $6.52 and a 200 day simple moving average of $7.94.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Monday, November 2nd. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. The business had revenue of $110.00 million for the quarter, compared to the consensus estimate of $123.22 million. Emergent Biosolutions had a negative return on equity of 0.43% and a negative net margin of 40.16%. As a group, sell-side analysts forecast that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

Insider Buying and Selling at Emergent Biosolutions

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction on Wednesday, October 7th. The stock was sold at an average price of $7.09, for a total value of $126,202.00. Following the completion of the transaction, the director directly owned 111,921 shares of the company’s stock, valued at $793,519.89. The trade was a 13.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On Emergent Biosolutions

Hedge funds and other institutional investors have recently modified their holdings of the business. Integrated Wealth Concepts LLC bought a new stake in shares of Emergent Biosolutions during the second quarter valued at approximately $29,000. Public Employees Retirement System of Ohio acquired a new position in shares of Emergent Biosolutions during the second quarter worth approximately $36,000. Legal & General Group Plc acquired a new position in shares of Emergent Biosolutions during the second quarter worth approximately $44,000. Tocqueville Asset Management L.P. bought a new position in shares of Emergent Biosolutions in the 2nd quarter worth $93,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Emergent Biosolutions in the 2nd quarter worth $115,000. Institutional investors own 78.40% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.